Williamson v. Sanofi Winthrop Pharmaceuticals, Inc.

60 S.W.3d 428, 347 Ark. 89, 2001 Ark. LEXIS 641
CourtSupreme Court of Arkansas
DecidedNovember 29, 2001
Docket01-345
StatusPublished
Cited by66 cases

This text of 60 S.W.3d 428 (Williamson v. Sanofi Winthrop Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of Arkansas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Williamson v. Sanofi Winthrop Pharmaceuticals, Inc., 60 S.W.3d 428, 347 Ark. 89, 2001 Ark. LEXIS 641 (Ark. 2001).

Opinion

J IM HANNAH, Justice.

Appellant Robert Williamson 1 appeals the Pulaski County Circuit Court’s decision denying class certification to a group of employees from Sanofi Winthrop Pharmaceuticals, Inc. (Sanofi), the appellee. The trial court found that Williamson could not. meet the requirements of establishing commonality and superiority for class certification. We affirm.

This case centers around a bonus program for pharmaceutical sales people. During 1996, Sanofi held a sales promotion known as “Share in the Success.” Under the program, sales representatives could earn $1,000, $2,000, or $4,000 bonuses if their sales region exceeded its performance from the previous year. Each of three regions had the opportunity to exceed a budgeted regional growth objective from the prior year in three business units: cardiovascular, injectable, and specialty products. Williamson worked in Central Region-2, which contained approximately sixty-three commissioned sales people.

As part of the program, Sanofi first published a booklet entitled “1996 Sales Incentive Program,” which described the program as depending on increased sales as compared to a regional standard. However, throughout the following year as the program was ongoing, Sanofi distributed monthly reports to each salesperson detailing each person’s performance for the month, and updating how each region was doing in the program. Sanofi hired the outside firm Simulate, Inc., to prepare the monthly reports. Unfortunately, while the program was created to be based on a “regional” growth objective, Simulate’s reports sent to each sales person were based on the national growth objective, which for some was an easier standard to meet. Every one of Williamson’s reports indicated that his sales were above the national average and that he was on track to receive the year-end $4,000 bonus. The dispute in this case stems from this series of incorrect reports. While the “Share in the Success” program required a certain increase in regional sales over the year, the reports contained a comparison to the “national” performance for all three business units.

In early 1997, Sanofi notified Williamson and other employees that they would be receiving their incentive payouts on May 15, 1997. In fact, Williamson received a phone call on May 12, 1997, from a manager who told him that he and others would receive the payment. However, before payment was made, Sanofi realized the mistake in the reporting of the program and denied payment. Specifically, Sanofi found that each salesperson’s monthly reports tracked his or her sales compared to the national average, but did not track each to the regional growth objective, which was higher than the previous year’s national averages in each business group.

Williamson filed a complaint on .March 30, 1998, alleging a breach-of-contract claim and asking that the court certify the commissioned sales representatives as a class. Sanofi answered on April 29, 1998, claiming that the class should not be certified, and that Williamson and the other sales people did not qualify for the incentive bonus because they did not meet the projected regional sales requirements. Sanofi also noted that the incorrect monthly reports were prepared by a third party.

On June 28, 2000, Williamson filed a specific motion to certify the class. Sanofi responded on August 16, 2000, arguing that each potential class member was not necessarily in the same position as another because it is unclear whether they each entered into a contract or believed that they entered into a contract merely by raising their sales numbers after the program was started. A hearing was held on this motion on August 21, 2000, at which no witnesses testified. After discussion of the elements to certify a class under Ark. R. Civ. P. 23, the trial court ruled from the bench that he did not find that there was a common question among the potential class members because each member may have had a different understanding of the incentive program or may have known that the reported numbers were in error. The trial court filed its written order on August 24, 2000, and stated the same. The trial court also found that a class action was not the superior method for adjudicating the claims of the individual plaintiffs. Williamson filed his notice of appeal on September 22, 2000.

On appeal, Williamson lists the six Rule 23 requirements for certifying a class, and argues that the trial court erred in failing to certify the class due to a lack of commonality in claims by the potential class members. While he lists all six Rule 23 requirements to satisfy class-action status, he offers little if any argument for the other five elements. On the commonality issue, Williamson argues that the questions of law and fact are similar for each potential class member as they each qualified for the incentive program, they are all employees of Sanofi, and none of them received payment under the program. Williamson argues that merely by increasing sales, each potential class member accepted the “offer” proposed by Sanofi so that a contract was formed. Sanofi responds that this case does not lend itself to a class action because it requires each sales person to establish that he or she believed that the program had changed so that the national performance numbers replaced the regional performance numbers. Sanofi argues that the bar graphs in the graphic comparisons mailed to each employee demonstrated that the region did not meet the regional sales growth criteria, although the narrative above the graph indicated that the sales were compared to the national performance for each product. Because of this, Sanofi argues that each employee’s understanding of the program and how and whether it applied to him or her is an individual question the court would have to ask each person to determine if each person thought a contract was formed. Therefore, the action is not proper as a class action.

The issue before this court is only one of class certification. In our review of a trial court’s decision to grant class certification, we have said that trial courts are given broad discretion in matters of class certification, and we will reverse the trial court’s ruling only when the appellant can demonstrate an abuse of that discretion. BPS Inc. v. Richardson, 341 Ark. 834, 20 S.W.3d 403 (2000); Baker v. Wyeth-Ayerst Laboratories Division, 338 Ark. 242, 992 S.W.2d 797 (1999); Seeco, Inc. v. Hales, 330 Ark. 402, 954 S.W.2d 234 (1997); Mega Life & Health Ins. v. Jacola, 330 Ark. 261, 954 S.W.2d 898 (1997). Although we do not delve into the merits of the underlying claims in a potential class-action case, we will review the trial court’s order to determine whether the requirements of Rule 23 are satisfied. BPS, Inc., supra.

On the merits, Rule 23 of the Arkansas Rules of Civil Procedure details the requirements for a class-action suit. It states:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hatfield v. Tony Pirani
W.D. Arkansas, 2024
Everett Latham Hayes v. Robert Penska
2020 Ark. App. 216 (Court of Appeals of Arkansas, 2020)
Keith Savage v. State of Arkansas
2019 Ark. App. 532 (Court of Appeals of Arkansas, 2019)
Smelser v. Discover Bank
W.D. Arkansas, 2019
Holley v. Bitesquad.com LLC
E.D. Arkansas, 2019
Robinson Nursing & Rehabilitation Center, LLC v. Phillips
2017 Ark. 162 (Supreme Court of Arkansas, 2017)
City of Conway v. Shumate
2017 Ark. 36 (Supreme Court of Arkansas, 2017)
The Madison Cos., LLC v. Williams
2016 Ark. App. 610 (Court of Appeals of Arkansas, 2016)
Arkansas Department of Veterans Affairs v. Mallett
2015 Ark. 428 (Supreme Court of Arkansas, 2015)
Arkansas Department of Veterans Affairs v. Okeke
2015 Ark. 275 (Supreme Court of Arkansas, 2015)
Philip Morris Cos. Inc. v. Miner
2015 Ark. 73 (Supreme Court of Arkansas, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
60 S.W.3d 428, 347 Ark. 89, 2001 Ark. LEXIS 641, Counsel Stack Legal Research, https://law.counselstack.com/opinion/williamson-v-sanofi-winthrop-pharmaceuticals-inc-ark-2001.